Lymphoma, Large B-Cell, Diffuse  >>  OXS-1550  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
OXS-1550 / GT Biopharma
NCT00889408: DT2219ARL for Relapsed or Refractory CD19 (+), CD 22 (+) B-Lineage Leukemia Or Lymphoma

Completed
1
25
US
DT2219ARL
Masonic Cancer Center, University of Minnesota, National Cancer Institute (NCI)
Leukemia, Lymphoma
07/14
07/14

Download Options